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OBJECTIVES: To establish the rate of new and continua-
tion of benzodiazepine use in older adults seen by nonpsy-
chiatrist physicians and to identify subpopulations at risk
of new and continuation benzodiazepine use.
DESIGN: Cross-sectional analysis.
SETTING: National Ambulatory Medical Care Survey
(2007–10).
PARTICIPANTS: Adults visiting office-based nonpsychia-
trist physicians (n = 98,818) who were prescribed a benzo-
diazepine (new or continuation).
MEASUREMENTS: Percentage of benzodiazepine visits
of all outpatient encounters according to patient age and
corresponding annual visit rate per 1,000 population.
Analysis was then limited to adults aged 65 and older,
demographic, clinical, and visits characteristics were used
to compare visits of benzodiazepine users with those of
nonusers and visits of continuation users with those of
new users.
RESULTS: The overall proportion of benzodiazepine visits
ranged from 3.2% (95% confidence interval (CI) = 2.7–
3.7) of those aged 18 to 34 to 6.6% (95% CI = 5.8–7.6)
of those aged 80 and older, and the proportion of continu-
ation visits increased with age, rising to 90.2% (95%
CI = 86.2–93.1) of those aged 80 and older. The popula-
tion-based visit rate ranged from 61.7 (95% CI = 50.7–
72.7) per 1,000 persons in the youngest adults to 463.7
(95% CI = 385.4–542.0) in those aged 80 and older. Only
16.0% (95% CI = 13.5–18.8) of continuation users had
any mental health diagnosis. Of all benzodiazepine users,
fewer than 1% (95% CI = .4–1.8) were provided or
referred to psychotherapy, and 10.0% (95% CI = 7. 2–
13.3) were also prescribed an opioid.
CONCLUSION: In the United States, few older adult ben-
zodiazepine users receive a clinical mental health diagnosis,
and almost none are provided or referred to psychotherapy.
Prescribing to older adults continues despite decades of evi-
dence documenting safety concerns, effective alternative
treatments, and effective methods for tapering even chronic
users. J Am Geriatr Soc 64:2546–2553, 2016.
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Benzodiazepine use in the United States is common andincreases with age. In a recent analysis, 8.7% of U.S.
adults aged 65–80 were prescribed benzodiazepines over
the course of 1 year.1 Benzodiazepines are most commonly
used for anxiety and insomnia, even though psychotherapy
and alternative medications are recommended preferen-
tially.2–4 Use is a particular concern in older adults, given
associations between benzodiazepines and a variety of
adverse outcomes, including falls,5 fractures,6 motor vehi-
cle accidents,7 impaired cognition,8,9 and dementia.10 Due
to the accumulation of health and safety concerns in older
adults, the American Geriatrics Society (AGS) Beers Crite-
ria include a strong recommendation to avoid any type of
benzodiazepine for the treatment of insomnia or agitation,
allowing that use may be appropriate for a few select indi-
cations, including severe generalized anxiety disorder unre-
sponsive to other therapies.11 As part of the Choosing
Wisely Campaign, the AGS identified use of benzodi-
azepines in older adults as one of 10 things physicians and
patients should question.12
A recent analysis of national benzodiazepine prescribing
highlighted a rate of long-term use (≥120 days of medica-
tion dispensed during the year) that increased with age,
growing to nearly one-third of use in those aged 65 to 80.
This high rate in older adults at particular risk of harm
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reflects the challenges that patients and providers face
regarding discontinuing long-term benzodiazepines.13,14 In
addition to considering whether use is short or long term,
interventions to reduce benzodiazepine use in older adults
may need to be customized for factors such as indication for
the prescription and patient engagement in psychotherapy.
Prior studies based on self-report of regional samples have
suggested that insomnia15 and anxiety16 are the primary rea-
sons for a benzodiazepine prescription, although the studies
differed as to which indication was most common. The
extent to which benzodiazepine users engage in psychother-
apy is critical, because psychotherapy has been shown to be
effective in facilitating benzodiazepine taper,17 especially in
older adults whose indication for use is insomnia.18,19
Prior work on prevalence of benzodiazepine use in the
United States is based on data collected more than
20 years ago,20–22 and the recent national prescription
analysis had limited encounter-level clinical information.1
To the knowledge of the authors of the current study,
there are no previous studies of benzodiazepine use that
include information about psychotherapy. This article uses
data from the National Ambulatory Medical Care Survey
(NAMCS), a representative survey of visits to all office-
based physicians in the United States. Nonpsychiatric
physicians, who provide the vast majority of benzodi-
azepine prescriptions to adults, including nearly 95% of
those to older adults, were focused on.1 The proportion
and population-based rate of visits at which a benzodi-
azepine is prescribed in adult outpatient visits are
described, stratified according to age group. Demographic,
clinical, and visit characteristics associated with benzodi-
azepine use were examined to identify clinical subpopula-
tions at risk of benzodiazepine therapy and on whom to
focus discontinuation initiatives. Finally, how continuation
benzodiazepine users differ from new users was examined,
to focus efforts that limit conversion to long-term use.
METHODS
Sample
These analyses used NAMCS (administered by the
National Center for Health Statistics (NCHS) from 2007
to 2010. NAMCS is a national probability sample survey
of office-based physicians designed to “provide objective,
reliable information about the provision and use of ambu-
latory medical care services in the United States.”23 Physi-
cians are sampled from the American Medical Association
and American Osteopathic Association master files. The
specialties of anesthesiology, pathology, and radiology are
excluded from the survey, as are encounters such as house
calls or those to institutional settings (e.g., nursing homes).
Each physician is randomly assigned to a 1-week
reporting period, with data collected from a systematic
random sample of visits during that week. The physician
or office staff record data on patient age, sex, and race
and ethnicity for selected visits on a standardized form.
The overall physician response rate over the 4 years ran-
ged from 58.3% to 62.1% and yielded a total of 125,029
encounters. Adjusting for survey design elements allows
analyses to represent total annual visits to U.S. office-based
physicians.24
Benzodiazepines and Other Medications
Survey data include information on up to eight medica-
tions that are prescribed, ordered, supplied, administered,
or continued during each visit. Visits were considered ben-
zodiazepine visits if the medication list included any of the
following: alprazolam, chlordiazepoxide, clonazepam, clo-
razepate, diazepam, estazolam, flurazepam, halazepam,
lorazepam, midazolam, oxazepam, prazepam, quazepam,
temazepam, or triazolam. Each visit was classified as to
whether the benzodiazepine was newly prescribed at that
visit or continued (previously prescribed), as well as
whether other common psychotropic medications were
prescribed (new or ongoing), including antidepressants,
antipsychotics, and opioids (Table S1). The total number
of continued medications at the visit was also calculated
(excluding benzodiazepines).
Diagnosis and Reason for Visit
Up to three visit diagnoses were recorded (using the Inter-
national Classification of Diseases, Ninth Revision, Clini-
cal Modification) along with up to three things the patient
described as the most important reason for the visit, which
survey field staff coded using a classification system devel-
oped at NCHS.25 Encounters were identified as being for
anxiety, insomnia, depression, substance use disorders,
dementia, and any mental health diagnosis or reason for
visit (Table S2).
Beyond the three or fewer specific visit-related diag-
noses, NAMCS collects data on several chronic conditions
at all visits, which were included to more fully capture
medical comorbidity: asthma or chronic obstructive pul-
monary disease, cerebrovascular or ischemic heart disease,
hypertension or hyperlipidemia, congestive heart failure,
obesity, osteoporosis, and tobacco use.
Provider and Visit Characteristics
NAMCS classifies providers into 15 specialty groups. Anal-
ysis was limited to nonpsychiatric providers, grouped as
family medicine, internal medicine, and other specialty.
Other visit-related information used for analysis included
whether the visit was a return visit, how many times the
patient had been seen in the previous 12 months, whether
the visit was to address a chronic problem; whether a
return visit was scheduled, whether psychotherapy or other
mental health counseling was provided or ordered,
whether stress management health education was provided
or ordered, and visit duration (minutes of face-to-face con-
tact).
Statistical Methods
The sample was limited to visits to nonpsychiatrist physi-
cians by people aged 18 and older from 2007 to 2010
(n = 98,818) stratified according to age (18–34, 35–49,
50–64, 65–79, ≥80). National benzodiazepine visit esti-
mates and corresponding 95% confidence intervals (CIs)
were generated. Analyses were adjusted using survey
design elements that NCHS provides for visit weight, clus-
tering within physician practice, and stratification to allow
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national inferences.24 Survey years were combined as
NCHS recommend to produce more-reliable annual visit
rate estimates.26 The proportion that these benzodiazepine
visits represented of all office-based physicians’ visits and
the proportion of visits that were new versus continuation
treatment were estimated. Using denominators (noninstitu-
tionalized population for each age group) obtained from
U.S. Census estimates,27 annual visit rates per 1,000 popu-
lation were generated.
Analysis was then limited to adults aged 65 and older
(n = 32,544), and logistic regression was used to test
the association between individual characteristics and ben-
zodiazepine therapy. Any benzodiazepine prescribing
(dependent variable: 0 = nonuser, 1 = user) and type of pre-
scribing (dependent variable: 0 = new, 1 = continuation)
were compared. Multivariable logistic regression was used
to adjust for anxiety and insomnia, the most-common clini-
cal indications for which benzodiazepines are prescribed.
People may have multiple conditions addressed during
a visit, but NAMCS collects information on only up to
three diagnoses and three self-reported visit reasons. A sen-
sitivity analysis of the association between diagnoses and
visit types was conducted by limiting analysis to visits with
two or fewer diagnoses or self-reported reasons for visit
(Tables S3, 4). Analyses were conducted using Stata ver-
sion 13.1 (Stata Corp., College Station, TX) using two-
sided tests with a = .05.
RESULTS
Benzodiazepines were prescribed at 5.6% (95% CI = 5.2–
6.0%) of adult outpatient physician visits, representing
approximately 20.4 (95% CI = 17.0–23.9) million visits
annually. The percentage of visits at which new benzodi-
azepines were prescribed decreased with age, and continu-
ation benzodiazepine use accounted for an increasingly
large proportion (Table 1). The per-population benzodi-
azepine visit rate per 1,000 persons was lowest for young
adults (61.7, 95% CI = 50.7–72.7) and increased mark-
edly with age to 463.7 (95% CI = 385.4–542.0) in the
oldest adults (Figure 1). The rate of new benzodiazepine
visits was relatively constant across age groups; the
increase in the overall benzodiazepine visit rate of older
adults was largely due to the increasing rate of continua-
tion visits.
Benzodiazepine users were more likely to be older and
female than nonusers (Table 2). Benzodiazepine users had
higher rates of mental health diagnoses or reasons for vis-
its, although overall, few visits had such diagnoses
(Table 3); 8.2% (95% CI = 6.4–10.5%) of benzodiazepine
users had anxiety as a diagnosis or visit reason, and 3.5%
(95% CI = 2.5–4.9%) reported insomnia. In the sensitivity
analysis limited to visits with two or fewer diagnoses or
visit reasons, similar associations between diagnosis and
benzodiazepine use were observed (Table S3).
More than one-quarter (95% CI = 24.6–29.3%) of
visits by individuals prescribed benzodiazepines included a
prescription for an antidepressant and 10.0% (95%
CI = 7.4–13.3%) for an opioid. A small proportion of
benzodiazepine visits included psychotherapy (0.8%, 95%
CI = 0.4–1.8%) or stress management health education
(3.6%, 95% CI = 2.2–5.9%).
Older adults prescribed a benzodiazepine appeared to
be more medically ill, with higher proportions of chronic
conditions, more visits within the past 12 months, and
receipt of more prescription medications.
There was no association according to age or sex
between continuation and new benzodiazepine visits
(Table 2), although the odds of continuation use at a visit
for a non-Hispanic black person were significantly lower
than for a non-Hispanic white person, because the propor-
tion of new benzodiazepine use by non-Hispanic black
individuals was higher than continuation use. Visits by
continuation and new users were largely similar across
clinical and visit characteristics, but visits by continuation
benzodiazepine users were far less likely to have any men-
tal health diagnosis, anxiety, or insomnia (Table 4). When
comparisons between new and continuation visits were
limited to visits with two or fewer diagnoses or reasons
(Table S4), the overall difference and statistical significance
was little changed from results in the full sample.
Individuals at a continuation visit were more likely
than those at a new benzodiazepine visit to receive an
antidepressant, equally likely to receive or be referred to
psychotherapy, and less likely to receive stress manage-
ment health education.
Table 1. Benzodiazepine Visits of All Adults, According to Age, to Office-Based Nonpsychiatric Physicians in the
United States from 2007 to 2010 (N = 98,818)
Visits 18–34 35–49 50–64 65–79 ≥80 F P-Value
Overall, n 17,156 21,447 27,671 22,895 9,649
Benzodiazepine, n 547 1,271 1,639 1,194 554
Benzodiazepine,
%a (95% CI)
3.2 (2.7–3.7) 6.2 (5.7–6.8) 6.2 (5.6–6.9) 5.6 (4.9–6.3) 6.6 (5.8–7.6) 23.8 <.001
Continuation,
%b (95% CI)
70.3 (64.0–75.9) 80.0 (76.9–82.8) 83.4 (78.6–87.2) 86.3 (81.7–90.0) 90.2 (86.2–93.1) 9.3 <.001
New, % (95% CI) 29.8 (24.1–36.1) 20.0 (17.3–23.1) 16.6 (12.8–21.4) 13.7 (10.1–18.3) 9.8 (6.9–13.9)
aWeighted percentage of overall visits.
bWeighted percentage of all benzodiazepine visits (e.g., of encounters at which a benzodiazepine was prescribed for those aged 18–34, 70.3% were contin-
uation prescriptions). New and continuation percentages within age groups may not add to 100% because of rounding.
CI = confidence interval.
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Continuation users were taking a larger number of
other medications but had a level of medical comorbidity
similar to that of new users with the exception of asthma
or chronic obstructive pulmonary disease (COPD), which
was more common in continuation visits. There were no
statistically significant differences between the new and
continuation groups according to provider type or other
visit characteristics.
DISCUSSION
These analyses demonstrate that the population-based rate
of new benzodiazepine use in U.S. office-based medical
practice is generally consistent across adult age groups.
Despite evidence of the harms associated with benzodi-
azepine use in older adults, efficacy of alternative pharma-
cotherapy and psychotherapy,2–4,28 and professional
guidelines advising against benzodiazepines,11,12 initiation
continues unabated, and continuation prescriptions
account for a growing proportion of use with older age.
Prior work has suggested that benzodiazepine use in
older adults is primarily for anxiety or insomnia.15,16,22
The current findings confirm that anxiety and insomnia
are the most common diagnoses and reasons reported for
a benzodiazepine visit, at 21.3% and 11.6%, respectively,
of new benzodiazepine visits, although there was no men-
tal health–related diagnosis or reason for visit reported in
more than 80% of all benzodiazepine visits and in nearly
60% of visits at which a new benzodiazepine was started.
It may be that some benzodiazepines are started for brief
stress or adjustment reactions that clinicians are not
recording as a diagnosis. In a previous analysis of commu-
nity-dwelling individuals newly started on an anxiolytic,
the most common reason reported after anxiety or insom-
nia was “stressful life event, adjustment, [or] grief,”16
although if the individuals reported a visit reason such as
stress or tension, this should have been captured in the
survey data (Table S2, code 1100.0). Another possibility is
that older adults may report not anxiety but instead a vari-
ety of somatic symptoms.29 Providers may conceptualize
and treat such symptoms as anxiety but not label them as
such. The continuation benzodiazepine user appears to be
taking “benzodiazepine[s] for less specific indications”
than well-defined psychiatric disorders, as noted previ-
ously.22
What is perhaps most notable—and has not previously
been reported to the knowledge of the authors—is the
extremely small proportion of individuals who received or
were referred to psychotherapy. Cognitive behavioral ther-
apy,28,30 short-term psychodynamic therapy,31 and other
psychosocial treatments29 are all effective for anxiety dis-
orders, and cognitive behavioral therapy is effective for
insomnia.4 Despite the efficacy of psychotherapy to treat
the most common conditions for which benzodiazepines
are prescribed, fewer than 1% of overall and new benzodi-
azepine visits included provision of or referral to psy-
chotherapy. Nonpsychiatrist physicians may benefit from
additional education about the effectiveness of evidence-
based psychotherapies and, perhaps more importantly,
improved access for their patients to such treatments.
NAMCS may underestimate the provision of psychother-
apy, because people may be engaged in psychotherapy
with another provider, or psychotherapy may have been
previously discussed or attempted. In addition, nonphysi-
cian providers provide a significant amount of psychother-
apy, which NAMCS does not capture. Nevertheless, adults
aged 65 and older have the lowest rates of psychotherapy
use of any age group, and the NAMCS-based rate is simi-
lar to a previous analysis of psychotherapy using data





































Figure 1. Annual population-based visit rates according to age group for new and continuation benzodiazepine use by patients
of nonpsychiatrist physicians in the United States from 2007 to 2010 (n = 5,205).
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In addition to psychotherapy as an alternative to ben-
zodiazepines, selective-serotonin reuptake inhibitors are
considered first-line pharmacotherapy for anxiety disor-
ders.33,34 Among all benzodiazepine visits, just one-quarter
of individuals were taking an antidepressant. The low pro-
portion of participants receiving psychotherapy and the
low proportion of those taking antidepressants suggest that
older adults are not receiving treatments that are more
appropriate and safer than benzodiazepines.
Nearly 10% of those prescribed a benzodiazepine
were also prescribed an opioid, and co-prescription of
antipsychotics occurred in 3% of older adults. Co-prescrib-
ing of such central nervous system–active medications is
associated with cognitive decline,35 and use singly5,6,36 or
in combination11 is associated with greater risk of falls
and fractures. An added concern is their role in pharma-
ceutical overdose deaths. Individually, opioids and benzo-
diazepines are involved in more than 75% of
pharmaceutical overdose deaths.37 In opioid-related
deaths, which are the leading type of pharmaceutical
death, benzodiazepines are the most commonly co-pre-
scribed medication, involved in 30% of deaths. Although
combination use of these agents may be appropriate in
select populations, use should be considered only after
fully discussing potential risks, benefits, and alternatives.
There were few differences in other clinical character-
istics between new and continuation benzodiazepine users.
A larger proportion of continuation users have asthma or
COPD, which is consistent with the high prevalence of
anxiety disorders in individuals with chronic respiratory
problems,38 although it is also possible that respiratory
symptoms may be misattributed to anxiety, leading to ben-
zodiazepine treatment. Nonetheless, use of benzodi-
azepines in individuals with COPD is troubling given the
association with mortality.39
Likewise, there are few visit characteristics that distin-
guish between benzodiazepine users and nonusers or new
and continuation users. Visits with benzodiazepine users
were slightly longer than those with nonusers, and new
visits were slightly longer than continuation visits, but nei-
ther comparison was statistically significant or clinically
meaningful. There was no difference according to visit dis-
position or whether the individual was established with
the practice. Those taking a benzodiazepine had had more
visits in the prior 12 months than nonusers, which is con-
sistent with their higher overall medical comorbidity, but
there was no difference between new and continuation
benzodiazepine users.
This work has several limitations. First, individual-
level clinical assessments of current symptoms and func-
tion were not available. Second, visit diagnoses were lim-
ited to three, so in individuals with more active problems,
there may be information bias that affects the various ben-
zodiazepine groups differently. However, when limiting
analysis to encounters with no more than two diagnoses
or visit reasons, the associations between diagnoses and
benzodiazepine use were virtually unchanged. Third,
NAMCS does not account for whether a prescribed medi-
cation is taken regularly versus as needed, so it is possible
that the extent of use is overestimated. However, because
only eight medications are recorded, benzodiazepine use
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survey of office-based practice, it does not include physi-
cians practicing in other settings. Although physician non-
response might introduce bias into the results, the survey
weights that NAMCS designed account for this to produce
unbiased national estimates.24 Finally, although the analy-
sis was limited to nonpsychiatrist physicians, it is possible
that psychiatrists initially prescribed some of the continua-
tion benzodiazepines. Nevertheless, because nearly 95% of
new benzodiazepines prescribed to older adults are from
nonpsychiatrists,1 it is likely that the psychiatrist-initiated
group accounts for a small subset.
These nationally representative analyses largely con-
firm and update analyses using data from more than
20 years ago by demonstrating that benzodiazepine initia-
tion continues into late life, continuation use increases
with age, and benzodiazepines are prescribed for purposes
other than clearly defined mental disorders.22,40 How can
continued use of a potentially harmful intervention, in the
face of extensive evidence that alternatives are effective
and safer, be explained? A previous study13,14 of older
adults who were chronic benzodiazepine users suggested
that people doubted that “[any]thing other than the benzo-
diazepine” would help and generally rejected the idea of
psychological interventions. The majority of physicians
“believed that attempting withdrawal would be time-con-
suming and likely futile.” These attitudes are frustrating
given the growing evidence that older adults, even those
with chronic use, can successfully decrease and be tapered
off benzodiazepines using interventions including cognitive
behavioral therapy and direct-to-consumer educational
techniques.17–19,41 As attitudes about mental health disor-
ders and treatment change, it may be that older adults will
become more willing to consider psychotherapeutic treat-
ment options. However, this will not be helpful if they
have no access to specialty mental health services.42
Although people may be reluctant to stop long-term
benzodiazepine use, a physician’s fundamental responsibil-
ity is to the safety of his or her patient. The majority of
use appears to be in the absence of a clearly defined men-
tal disorder, with limited use of alternative and safer treat-
ments such as antidepressants or psychotherapy. Although
clicking “reorder” may limit short-term patient (and
Table 3. Association Between Clinical and Visit Characteristics and Benzodiazepine Use in Older Adult Patients of












Diagnosis or visit complaint, %
Anxiety 8.2 0.8 <.001 10.74 (7.69–15.00)
Insomnia 3.5 0.7 <.001 4.22 (2.82–6.30)
Depression 5.2 1.3 <.001 3.09 (2.12–4.52)
Dementia 0.5 0.5 .77 1.11 (0.46–2.67)
Substance use disorder 0.5 0.2 .11 1.68 (0.66–4.29)
Any mental health diagnosis 19.0 4.8 <.001 2.77 (2.17–3.54)
Medical condition
Asthma, chronic obstructive pulmonary disease 18.2 11.7 <.001 1.71 (1.38–2.11)
Cerebrovascular accident, coronary artery disease 16.7 13.6 .005 1.28 (1.09–1.52)
Hypertension, HL 67.5 58.2 <.001 1.50 (1.26–1.78)
Congestive heart failure 5.7 5.0 .27 1.17 (0.92–1.49)
Obesity 5.4 5.9 .54 0.94 (0.69–1.29)
Osteoporosis 9.8 6.3 <.001 1.56 (1.26–1.93)
Tobacco use 8.8 5.7 <.001 1.57 (1.22–2.02)
Other psychotropic medication
Antidepressant 26.9 7.8 <.001 3.93 (3.40–4.55)
Antipsychotic 2.6 0.8 <.001 3.41 (2.16–5.39)
Opioid 10.0 2.9 <.001 3.71 (2.63–5.24)
Total continued medications, mean (SEM) 4.6 (0.1) 3.6 (0.1) <.001 1.10 (1.10–1.16)
Visit
Psychotherapy 0.9 0.3 .009 1.68 (0.74–3.82)
Stress management 3.6 1.2 <.001 2.04 (1.28–3.27)
Provider
Family practice (reference) 24.5 18.0 1.00
Internal medicine 30.6 21.8 .75 1.05 (0.84–1.31
Specialty 44.9 60.2 <.001 0.63 (0.51–0.77)
Return visit with provider (reference new patient) 91.8 90.1 .28 1.12 (0.84–1.50)
Visit for a chronic condition 56.0 52.7 .09 1.13 (0.97–1.32)
Visit disposition: scheduled follow-up 78.1 77.2 .56 1.05 (0.89–1.25)
Number of visits in past 12 months, mean (SEM) 5.2 (0.2) 4.3 (0.1) <.001 1.03 (1.02–1.04)
Time with physician, minutes, mean (SEM) 20.9 (0.8) 19.9 (0.3) .08 1.00 (1.00–1.01)
aAdjusted for diagnosis or reason for visit of anxiety and insomnia.
bOdds of benzodiazepine use.
SEM = standard error of the mean.
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provider) distress, there are critical concerns regarding the
appropriateness and safety of most long-term benzodi-
azepine use in older adults in the United States. New
strategies are needed to encourage patients and providers
to discontinue potentially inappropriate benzodiazepine
therapy.
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Dementia 0.6 0.2 .11 2.90 (0.58–14.54)
Substance use disorder 0.4 1.1 .35 0.43 (0.03–6.55)
Any mental health diagnosis 16.0 40.3 <.001 0.48 (0.26–0.89)
Medical condition
Asthma, chronic obstructive pulmonary disease 19.2 10.6d .05 1.80 (0.87–3.74)
Cerebrovascular accident, coronary artery disease 17.3 12.2 .20 1.30 (0.68–2.48)
Hypertension, hyperlipidemia 67.2 69.9 .54 0.85 (0.54–1.32)
Congestive heart failure 5.9 4.3 .62 1.22 (0.37–4.02)
Obesity 5.4 5.4 .99 0.89 (0.48–1.65)
Osteoporosis 9.5 11.8 .40 0.76 (0.43–1.35)
Tobacco use 8.7 9.3 .85 0.87 (0.43–1.75)
Other psychotropic medication
Antidepressant 28.4 16.4 .007 2.05 (1.22–3.46)
Antipsychotic 2.8 1.2 .41 1.94 (0.26–14.67)
Opioid 8.7 19.3 .10 0.31 (0.10–0.96)
>1 benzodiazepine 3.8 7.9d .03 0.46 (0.22–0.94)
Total continued medications, mean (SEM) 4.9 (0.1) 2.2 (0.3) <.001 1.60 (1.41–1.84)
Visit
Psychotherapy 0.9 1.0 .90 1.66 (0.23–12.03)
Stress management 2.8 9.0 .002 0.50 (0.19–1.34)
Provider
Family practice (reference) 23.6 30.4 1.00
Internal medicine 31.0 27.8d .17 1.38 (0.78–2.46)
Specialty 45.4 41.7 .31 1.08 (0.56–2.11)
Return visit with provider (reference new patient) 92.2 85.4 .24 2.56 (0.79–8.29)
Visit for a chronic condition 56.8 50.3 .22 1.42 (0.92–2.19)
Visit disposition: scheduled follow-up 79.1 71.3 .10 1.53 (0.87–2.70)
Number of visits in past 12 months, mean (SEM) 5.3 (0.2) 4.4 (0.4) .13 1.04 (0.99–1.10)
Time with physician, minutes, mean (SEM) 20.6 (.9) 22.7 (1.4) .30 0.99 (0.98–1.00)
aAdjusted for diagnosis or reason for visit of anxiety and insomnia.
bOdds of continuation of benzodiazepine use.
SEM = standard error of the mean.
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